Screener / SEC EDGAR /CIK 0000818479 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Dental Equipment & Supplies

DENTSPLY SIRONA Inc. XRAY

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of XRAY's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Sep 14, 2023
Questions asked 4 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 4 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 2 of 2 closing letter

Half the closed reviews took 36 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2022

2023-09-14 to 2023-09-29 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2023-09-29
Non-GAAP measures
Exhibit 99.1, page 1
SEC asked (1)
You present Adjusted EBITDA Margin in the bullet points at the top of Exhibit 99.1 without the presentation of the corresponding GAAP measure. Revise here and in your Q2 23 Summary Results tables in future Earnings Releases to also present gross margin on a GAAP basis. Ensure that your presentation of the GAAP measure is presented with equal or greater prominence than the non-GAAP measure.
Rest of the question

We refer you to Item 10(e) of Regulation S-K.

XRAY answered
September 28, 2023 VIA EDGAR SUBMISSION U.S. Securities & Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC Attn: Julie Sherman and Brian Cascio Re: DENTSPLY SIRONA Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 1, 2023 Form 8-K Dated August 2, 2023 Filed August 2, 2023 File No. 000-16211 Dear Ms. Sherman and Mr.
Rest of the letter

Cascio, This letter responds to comments of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in a letter dated September 14, 2023, regarding the abovereferenced Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”) and Form 8-K dated August 2, 2023 (the “Form 8-K”) of DENTSPLY SIRONA Inc. (the “Company”). We have reproduced the Staff’s comments below in bold and provided our response immediately below. Form 8-K filed August 2, 2023 Exhibit 99.1, page 1 1. You present Adjusted EBITDA Margin in the bullet points at the top of Exhibit 99.1 without the presentation of the corresponding GAAP measure. Revise here and in your Q2 23 Summary Results tables in future Earnings Releases to also present gross margin on a GAAP basis. Ensure that your presentation of the GAAP measure is presented with equal or greater prominence than the non-GAAP measure. We refer you to Item 10(e) of Regulation S-K. The Company advises the Staff that for the three months ended June 30, 2023, gross margin was 53.5%. The Company confirms that in future filings the Company will provide the corresponding GAAP measure before Adjusted EBITDA Margin with equal or greater prominence, as well as appropriate GAAP to Non-GAAP reconciliations. The Company expects that the reconciliation of gross profit for the three months ended June 30, 2023 will be substantially similar to the reconciliation included in Appendix A, which has been included for the Staff’s reference. 2 2. Your presentation of ‘Adjusted Non-GAAP’ amounts appear to represent non-GAAP income statements. Please note that the presentation of a full non-GAAP income statement, or a presentation that gives the appearance of one, may place undue prominence on the non-GAAP information and give the impression that the non-GAAP income statement represents a comprehensive basis of accounting. Please explain to us how your presentation complies with Question 102.10 of the C&DI’s on Non-GAAP Financial Measures. To the extent you wish to present any of the non-GAAP measures, you could present a separate reconciliation for each non-GAAP measure and provide all disclosures required by Item 10(e)(1)(i) of Regulation S-K. The Company acknowledges the Staff’s comment, and respectfully advise the Staff that the Company had considered Question 102.10 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations and the application of Regulation G and Item 10(e) of Regulation S-K (collectively, the “Non-GAAP Disclosure Guidance”) and believed that its presentation of “Adjusted Non-GAAP” amounts would not be considered a non-GAAP income statement. The Non-GAAP Disclosure Guidance indicates that presenting a full non-GAAP income statement when reconciling non-GAAP financial measures to GAAP financial measures could result in the disclosure of the non-GAAP financial measures being more prominent. The Company has not presented a full non-GAAP income statement in the reconciliation, and, in fact, the Company specifically excluded certain line items from the GAAP income statement, such as cost of products sold, in presenting the reconciliation. The Company believed the presentation of the reconciliation allowed it to specify the adjustments it was making to the GAAP financial measures, while also providing additional transparency to users of the reconciliation about their impacts within the income statement. However, after careful consideration of the Staff’s comment, in future filings the Company will make the following adjustments to its presentation of this reconciliation to ensure an impression is not given that the non-GAAP reconciliation represents a comprehensive basis of accounting: 1) We will remove additional line items from the reconciliation including Sales, General, and Administrative Expenses, Research and Development Expenses, Restructuring and Other Costs, and Other Income and Expense. 2) We will present the non-GAAP adjustments in the left column and each of the impacted line items horizontally within the table to further reduce any resemblance to a full income statement. The Company expects that the resulting table will be substantially similar to the reconciliation included in Appendix A, which has been included for the Staff’s reference. * * * 3 We acknowledge that the Company and its management are responsible for the adequacy and accuracy of the disclosure in documents filed and furnished to the Commission notwithstanding any review, comments, action or absence of action by the Staff. Thank you for your consideration of our response. If you have any questions or require any additional information with respect to the above, please do not hesitate to contact me, Lillian Tsu ([email protected]) or Francesca L. Odell ([email protected]), our counsel at Cleary Gottlieb Steen & Hamilton LLP. Sincerely, By: /s/ Glenn G. Coleman Glenn G. Coleman Executive Vice President and Chief Financial Officer DENTSPLY SIRONA Inc. (Registrant) Cc: Richard C. Rosenzweig Senior Vice President, Corporate Development, General Counsel and Secretary Dentsply Sirona Inc. Appendix A GAAP to Non-GAAP Reconciliation (unaudited) Three Months Ended June 30, 2023 (in millions, except per share amounts and percentages) Gross Profit Operating Income Net Income Attributable to Dentsply Sirona Diluted EPS GAAP ...................................... $ 550 $ 80 $ 86 $ 0.40 Non-GAAP Adjustments: Amortization of Purchased Intangible Assets ................... 30 53 39 0.18 Restructuring Related Charges and Other Costs..................... 3 20 3 0.01 Business Combination Related Costs and Fair Value Adjustments .......................... 1 7 10 0.05 Income Tax Related Adjustments .......................... — — (29) (0.13) Adjusted Non-GAAP ............. $ 584 $ 160 $ 109 $ 0.51 GAAP Margin .......................... 7.8% Non-GAAP Margin .................. 15.6%

One letter for all the questions, without numbered answers. Read the reply
In its next report

First report after the company's reply of Sep 28, 2023: 10-Q filed Nov 2, 2023 ↗, against the 10-Q filed Aug 7, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1, page 1
SEC asked (2)
Your presentation of ‘Adjusted Non-GAAP’ amounts appear to represent non-GAAP income statements. Please note that the presentation of a full non- GAAP income statement, or a presentation that gives the appearance of one, may place undue prominence on the non-GAAP information and give the impression that the non- GAAP income statement represents a comprehensive basis of accounting.
Rest of the question

Please explain to us how your presentation complies with Question 102.10 of the C&DI's on Non-GAAP Financial Measures. To the extent you wish to present any of the non-GAAP measures, you could present a separate reconciliation for each non-GAAP measure and provide all disclosures required by Item 10(e)(1)(i) of Regulation S-K.

XRAY answered

See the reply above.

In its next report

First report after the company's reply of Sep 28, 2023: 10-Q filed Nov 2, 2023 ↗, against the 10-Q filed Aug 7, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-09-29

Form 10-K for the Fiscal Year Ended December 31, 2020

2021-12-13 to 2022-01-18 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2022-01-18
RevenueSegmentsResults discussion (MD&A)China
Management's Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 43
SEC asked (1)
We note you attribute a decline in sales volume, in part, to certain countries in Asia and that there other references in your filing to China. We also note on page 87 that geographic information represents revenues for shipments made by operating businesses located in the country or territory identified, including export sales, and that this disclosure does not include any information related to Asia or China.
Rest of the question

Please describe to us and revise disclosure in future filings to include discussion and analysis in quantitative and qualitative terms related to your revenues that are attributable to China pursuant to Item 303 of Regulation S-K, or explain to us why additional disclosure is not required. In addition, please explain to us whether there are any material concentrations of revenues included in "other foreign" net sales in Note 5 to your financial statements and describe to us in further detail your methodology for attributing revenues from external customers to individual countries. Refer to ASC 280-10-50-41.

XRAY answered
The Company acknowledges the Staff’s comment regarding our filing’s reference to China (page 70), and consideration of the requirement to provide additional discussion and analysis of revenues attributable to that country in accordance with Item 303 of Regulation S-K, should they be material. We note that revenues pertaining to China were 4.0%, 4.7% and 4.5%, of the Company’s net sales for fiscal 2020, 2019 and 2018, respectively.
Rest of the answer

We respectfully advise the Staff that our disclosures which reference China (on page 70) and “certain countries in Asia” (on page 43, referring primarily to China) were intended to provide a narrative context for the sequence of the Company’s experience with COVID-19 during 2020, specifically the fact that business lockdowns occurred first in limited areas, which included the countries named, and then more broadly across the globe beginning in the second quarter. As the revenues pertaining to China were not material to the overall revenues of the Company as defined by Regulation S-K Item 303, additional quantitative and qualitative analysis and disclosures were not provided. We will continue to monitor the materiality of drivers of revenue from China and other individual countries and will provide such disclosures should they become quantitatively or qualitatively material.

With regards to the Staff’s comment on whether material concentrations of revenue exist within the category of “Other Foreign” net sales as disclosed in Note 5, the Company advises the Staff that, pursuant to ASC 280-10-50-41, we disclosed separate revenue information for those countries which had significant net sales, using a threshold of 10% or greater of the Company’s consolidated net sales. For the fiscal year 2020, the United States and Germany accounted for 33.2% and 13.1% of the Company’s net sales, respectively. There was no other country with net sales that equaled or exceeded the 10% threshold. The next three countries with largest concentration of the Company’s net sales were: Japan 5.8%, France 4.5%, and China 4.0%. Furthermore, there were no qualitative factors that warranted any additional disclosures for these or any other countries. If, in future fiscal years, the net sales of any additional foreign country were to become quantitatively or qualitatively material, we will provide the necessary disclosure as required by ASC 280-10-50-41.

We also acknowledge the Staff’s request to describe to you in further detail our methodology for attributing revenues for external customers to individual countries. The amounts of net sales disclosed in Note 5 (page 87) are the sales made to external customers in those respective countries based on their “ship-to” information, or, in other words, the destination of shipments. This information is derived from the same transaction-level details contained in our books-of-account which are used to produce the Company’s financial statements. Based on the Staff’s comments, we will revise our future filings to more clearly describe our aforementioned methodology for attributing net sales (revenues) to individual countries, in note 5, as follows:

Net Sales reported below represent revenues from external customers in those respective countries based on the destination of shipments.

Read in the reply
In its next report

First report after the company's reply of Jan 12, 2022: 10-K filed Mar 1, 2022 ↗, against the 10-K filed Mar 1, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Consolidated Financial Statements · Revenue Recognition, page 75
SEC asked (2)
Please revise future filings to include all of the disclosures required by ASC 606-10-50, as applicable. For example, provide the qualitative and quantitative disclosure about the significant judgments and changes in judgments, including inputs and assumptions, related to your accounting for returns, rebates and discounts, as set forth in ASC 606-1050-1(b), 50-17, and 50-20, a description of the payment terms under
Rest of the question

50-12, and disaggregated revenue under 50-5.

XRAY answered
We acknowledge the Staff’s comment and will revise future filings to include additional disclosures in accordance with ASC 606-10-50, as applicable, including further disaggregation of revenue beyond the information previously provided in footnotes 1 and 5 to the consolidated financial statements.
Read in the reply
In its next report

First report after the company's reply of Jan 12, 2022: 10-K filed Mar 1, 2022 ↗, against the 10-K filed Mar 1, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2022-01-18

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 6 letters filed since 2021-12-13. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XRAY/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.